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• Global prevalence, risk, and mortality from smoking 
 
• Gender/Sex specific diseases associated with tobacco use 
 
• Gender/Sex specific reasons for smoking 
 
• Gender/Sex specific factors in treating tobacco use 
 
Global prevalence, risk, and mortality from 
smoking 
 
  
“Cigarettes are like women. The best ones are 
thin and rich.” 
 
American Tobacco Company advertising slogan, US, circa 1970  
“I’m no cowboy and I don’t ride horseback, but I like to 
think I have the freedom the Marlboro man exemplifies. 
He’s the man who doesn’t punch a clock. He’s not 
computerized. He’s a free spirit.”  
 
George Weissman, Former President and CEO, Philip Morris USA, 1978 
 
800 million adult men worldwide smoke cigarettes. Almost 20% of the world’s adult male 
smokers live in high-income countries, while over 80% are in low- and middle-
income countries.  
Nearly 200 million adult women smoke worldwide 


Global Mortality Estimates 
• In 2011, tobacco use killed almost 6 million people (80% 
of deaths occurring in low-and middle-income countries) 
 
• Tobacco use is responsible for up to 15% of all deaths 
among men and 7% of all deaths among women globally 
(smoking also causes almost 80% of male and nearly 
50% of female lung cancer deaths) 
 
• Approximately 600, 000 nonsmokers died in 2011 from 
involuntary exposure to secondhand smoke. 
 
“Tobacco caused 100 million deaths during the twentieth century, and if 
current trends continue, approximately 1 billion people will die during 
the twenty–first century because of tobacco use”  
 
    Tobacco Atlas 4th edition (www.tobaccoatlas.org) 
 Gender/Sex specific diseases associated with tobacco use 
 
#1 Lung cancer  
#2 Ischemic heart disease 
#3 Chronic airways  
obstruction1 Cancers1  Lung,  
Bronchus Lip, Oral cavity/pharynx 
Esophagus Larynx, trachea 
Cervix uteri Urinary bladder 
Stomach2 Colon2  
Leukemia2 Pancreas 
Kidney,  Liver2 
  other urinary 
Cardiovascular disease1 
Ischemic heart disease 
Cerebrovascular disease 
Rheumatic heart disease 
Atherosclerosis 
Hypertension  
Aortic aneurysm 
Pulmonary heart disease 
Other arterial disease 
 
Respiratory disease1 
Chronic airways obstruction 
Asthma 
Bronchitis/emphysema 
Pneumonia/influenza 
Respiratory tuberculosis 
Paediatric disease1 
Low birth weight 
Respiratory conditions-newborn 
Respiratory distress syndrome 
Sudden Infant Death Syndrome 
Reproductive Problems2  
Reduced fertility 
Spontaneous Abortion 
Placental abruption 
1.  Makomaski Illing EM, Kaiserman, MJ. Can J Public Health 2004;95:38-44. 
2.  Ghadirian, P (for Health Canada). Sleeping with a Killer: The Effects of Smoking on Human Health. Health Canada. Sept. 2002. 
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Lung cancer risk may be higher in women, 
both among smokers (shown here) and 
nonsmokers 
USDHHS (1989) Surgeon General’s Report: Reducing the health consequences of smoking. 
Relative risk of myocardial infarction for current 
smokers compared with never smokers, by sex 
 
Prescott et al. (1998) Smoking and risk of myocardial infarction in women 
and men: longitudinal population study. Brit Med J  316: 1043-1047 
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Disease risk I 
Meta-analyses examining the risk for a variety of diseases 
associated with smoking in English language studies: 
For smokers of <20 cigarettes per day, the rate ratio point 
estimate was1.42 for males and 1.77 for females. 
For smokers of ≥20 cigarettes per day, the point estimate was 
1.95 for males and 2.75 for females. 
The increase in risk from low to high levels of smoking was 
greater for females than for males. 
Mucha et al. (2006). Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. 
Disease risk II 
Meta-analyses examining the risk for cardiovascular diseases 
associated with smoking in Asian and Australian/New Zealand (ANZ) 
studies  
Lower mean daily cigarette consumption among females (10 in Asia; 15 in 
ANZ) compared with males (16 and 20, respectively)  
For both CHD and stroke, hazard ratios comparing smokers of ≥20 
cigarettes per day with non-smokers were higher for women than men. 
Asia Pacific Cohort Studies Collaboration (2005). Smoking, quitting, and the risk of cardiovascular disease among women and men in 
the Asia-Pacific region. 
Gender/Sex specific reasons for smoking 
Sex differences in factors which influence tissue response 
to nicotine (pharmacodynamics)  
• Female mice less sensitive to the acute effects of nicotine 
• Progesterone and 17b-estradiol were found to block nicotine’s 
antinociception in mice. Testosterone failed to do so.  
• Progesterone and 17b-estradiol blocked nicotine activation of a4b2 
     neuronal acetylcholine nicotinic receptors expressed in oocytes. 
2. Sex differences which lead to systemically higher or lower 
plasma nicotine levels (pharmacokinetics) 
• No significant difference was found in the number of cigarettes per day 
or CO levels between the sexes. 
• Females had significantly lower nicotine levels than males (16.9 ± 0.6 vs. 
21.1 ± 0.07, p < 0.01) 
• Female heavy smokers demonstrated higher -log nicotine/CO values (a 
representation of cost of smoking) compared with male heavy smokers 
(0.1 ± 0.02 vs. 0.02 ± 0.01 mg/L ppm, p < 0.05). 
Based on Perkins KA et al.  (1994) Pharmacology, Biochemistry & Behavior 47:  107-112
                    Responses for smoking under lean
reinforcement schedules (VR16, VR32) versus money (VR4)
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• Removal of lit cigarette cue decreases smoking reinforcement (VR) 
more in women tha  i men.  
 
Sex/Gender Differences in non-pharmacological stimuli 
and drug (i.e., conditioned responses) 
Based on Perkins KA et al. (1994) Pharmacology, Biochemistry & Behavior 47:107-112 
Biopychosocial (i.e., gender) factors which differentiate 
men and women 
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Common reasons boys start 
smoking: 
 
•peer pressure 
•misconceptions that smoking is cool or 
enhances popularity 
•easy access to tobacco products 
•cigarette pricing 
•tobacco marketing.  
 
Common reasons young women 
start smoking 
 
•Association with others (parents and 
friends) who smoke 
•Concern with weight, body image, or 
social acceptance 
•Interest in rebelling or stating 
individuality 
•Reaction to positive image of 
smoking in magazines, movies, and 
youth culture 
•Influence from cigarette marketing 
campaigns targeting women 
Gender/Sex specific factors in treating tobacco use 
Nicotine Replacement Therapy Outcome 
Two meta-analyses examining nicotine replacement therapy 
(NRT) for smoking cessation  Women less successful than 
men. 
 
1. Cepeda-Benito et al. (2004)  21 RCTs with different NRT 
products: 
 NRT more effective than placebo at each follow-up for men. 
 Benefits for women clearly evident only at 3- and 6-month. 
 at 6 month only in combination with high-intensity counselling.  
 At 12 month, NRT was not superior to placebo for women, 
regardless of counselling intensity. 
 Effect sizes decreased over time for both men and women, 
but the decline was statistically significant only for women. 
  
Cepeda-Benito et al. (2004). Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences 
between men and women.  
Nicotine Patch Therapy Outcome 
 
2. Perkins & Scott (2008)  14 RCTs with nicotine patch: 
 6-months abstinence rates for NRT versus placebo were 
20.1% versus 10.8% for men, and 14.7% versus 10.1% for 
women. 
 Increase in quitting due to nicotine versus placebo was only 
about half as large in women as in men (ORs: 2.2 versus 
1.6). 
 NNTs: 10 for men and 19 for women  almost twofold 
increase in the estimated number needed to treat for 
women relative to men to get one additional long-term 
abstinent ex-smoker. 
Perkins & Scott (2008). Sex differences in long-term smoking cessation rates due to nicotine patch. 
Bupropion Outcome 
Meta-analyses examining bupropion for smoking cessation 
 12 RCT’s with Bupropion 300mg SR versus Placebo: 
 Both women and men benefited from bupropion as 
compared to placebo. 
 Women and men benefited equally from bupropion 
treatment, no sex differences were found in its 
effectiveness. 
 However, women were less likely than men to quit smoking, 
regardless of treatment type. 
Scharf & Shiffman (2004). Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-
analyses of clinical trials of Bupropion SR 
Women-specific interventions 
Treatment  models Treatment  components 
Weight concerns/weight gain are 
greater in women than in men 
• Behavioural strategies to prevent weight gain; 
• Medications to prevent weight gain; 
• Cognitive strategies to reduce weight and body 
image concerns. 
Negative affect/depression present 
special challenges for women 
Strategies to reduce /cope with negative affect:  
• behavioural (e.g., exercise); 
• coping skills /stress management training 
• medication (e.g., bupropion) 
The psychological aspects of 
smoking and the cues associated 
with smoking present special 
challenges for women 
• Cognitive-behavioural strategies to manage 
situations which trigger craving.  
• Medication to reduce the rewarding effects of 
nicotine: Naltrexone 
Nicotine withdrawal is higher 
during the luteal than during the 
follicular phase of the menstrual 
cycle 
Scheduling the quit date according to the menstrual 
cycle  
Torchalla, Okoli, Bottorff, Qu, Poole, & Greaves (2011). Smoking cessation programs targeted to women: A systematic review. 
Treatment  models Treatment  components 
• Certain sociocultural populations 
are hard to reach.  
• Treatment needs to account for 
their characteristics. 
• Counselors must be able to 
communicate with them and act 
as role models. 
• Peer lay counselors who share commonalities 
with the target group (e.g. language, culture, 
attitudes, beliefs). 
• Socioculturally adapted materials and 
components 
Women receiving health services 
may be specifically receptive for 
proactive smoking cessation 
intervention.  
• Brief motivational interventions (counseling 
plus telephone calls / letters). 
• Additionally: tailored/gendered booklets, 
video/poster exposure. 
• Or: mailings / telephone calls only (no face-to-
face contact). 
 
Women-specific interventions 
Torchalla, Okoli, Bottorff, Qu, Poole, & Greaves (2011). Smoking cessation programs targeted to women: A systematic review. 
Outcomes 
 
• Programs addressing exercise, weight gain/-concerns: 
Promising results, at least in the short term. 
• Mood management / stress management : no significant main 
effect, especially when compared to contact-matched programs. 
Counselling x medication effects possible. 
• Matching the quit date to the menstrual cycle: no consistent 
effects. 
• Peer counselling: preliminary promising results. 
• Interventions without face-to-face contact: no medium- and 
long-term effects reported. 
• Brief interventions in public health clinics: significantly higher 
medium-term abstinence rates compared to usual care 
 
 
 
Torchalla, Okoli, Bottorff, Qu, Poole, & Greaves (2011). Smoking cessation programs targeted to women: A systematic review. 
Conclusions 
 Women-specific tobacco programs help women stop smoking.  
 The choice of treatment for an individual smoker can be guided by 
client’s preferences.  
 Health care providers should be encouraged to address women’s 
smoking proactively and in any setting.  
 Future research: 
 Identify those elements that are essential for designing women-
specific smoking cessation programs. 
 Develop more creative and multifaceted women-specific 
programs, addressing the full range mechanisms relevant for 
women’s smoking behaviour. 
 
 
Torchalla, Okoli, Bottorff, Qu, Poole, & Greaves (2011). Smoking cessation programs targeted to women: A systematic review. 
Description of study 
Author (Year) Design Sample 
size 
Components % Quit at 
EOT 
Rose & Hamilton, (1978) RCT 1445 Quit advice from Physician  31.8%* 
Li, et al., (1984) RCT 576 Behavioural Counseling 8.4%* 
Burling et al., (1991) RCT 39 Relapse Prevention + Nicotine fading + 
Contingency management 
26.3%* 
Pallonen et al., (1994) RCT 265 Self-help manual 25%* 
Jenkins et al., (1997) Pre-Post 2714 Media led anti-tobacco interventions 7.2% 
Kalman et al., (2001) RCT 36 Individuals counseling + Nicotine Patch + 
substance use counselling 
16.6% 
Stanton et al., (2004) RCT 561 Video + nicotine patch + support material 16.5%* 
Harding, Bensley, & Corigan, 
(2005) 
Cohort 69 Behavioural counselling + peer support + 
Nicotine replacement 
64% 
Loke & Lam (2005) RCT 758 Advice on encouraging husbands to quit 6.1% 
Richmond et al., (2006) Cohort 30 Behavioural counselling + Nicotine 
replacement + Bupropion 
37% 
Gershon Grand et al., (2007) Cohort 231 Behavioural counselling + Nicotine 
replacement + Bupropion 
36.4% 
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Discussion 
• Associations with Sex & Gender: 
– No study specifically designed the intervention with sex or 
gender in consideration.  
– No study examined sex or gender differences in outcomes 
among men  
– Three studies were ‘men-centred’ – two examined expectant 
fathers, and one study addressed ‘gay’ men. 
 
• Associations with smoking cessation : 
– The most effective studies utilized combinations of behavioural 
counselling, nicotine replacement therapy and peer support. 
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Future directions 
• Need for studies examining sex and gender differences 
in smoking cessation outcomes. 
 
• Development of ‘women- centred’ and ‘men-centred’ 
interventions, tailored appropriately to the targetted male 
and female populations. 
 
• Further exploration of gendered factors associated with 
smoking cessation interventions and outcomes. 
iTAG 2012 Annual Spring Meeting 
